Special Issue "New Insights of Liver Cancer and Its Treatment"

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: 15 October 2022 | Viewed by 586

Special Issue Editors

Prof. Dr. WaiMing Tai
E-Mail Website
Guest Editor
1. National Cancer Centre Singapore, Singapore City, Singapore
2. Duke-NUS Medical School, Singapore City, Singapore
Interests: gastrointestinal malignancies; biomarker; novel therapeutics; translational personalized medicine
Prof. Dr. Joycelyn Lee
E-Mail Website
Co-Guest Editor
1. National Cancer Centre Singapore, Singapore City, Singapore
2. Duke-NUS Medical School, Singapore City, Singapore
Interests: hepatopancreatobiliary cancers; immuno-oncology; microbiome in cancer; supportive care

Special Issue Information

Dear Colleagues,

There has been an avalanche of novel insights pertaining to liver cancer and stage-dependent multimodality treatments. This has been possible with findings stemming from basic science, translational research, and clinical trials. This Special Issue of Current Oncology aims to provide reviews on novel insights of liver cancer and its treatment. We invite researchers to address either one of the following topics or a related topic:

  • Basic science of hepatocellular carcinoma.
  • Translational research.
  • Surgical techniques and transplantation.
  • Locoregional therapies.
  • Systemic therapies.
  • Predictive biomarkers.

Prof. Dr. WaiMing Tai
Prof. Dr. Joycelyn Lee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatocellular carcinoma
  • basic science
  • translational research
  • preclinical models
  • predictive biomarkers
  • surgery
  • locoregional therapies
  • systemic therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond
Curr. Oncol. 2022, 29(8), 5489-5507; https://doi.org/10.3390/curroncol29080434 - 04 Aug 2022
Viewed by 400
Abstract
Hepatocellular carcinoma (HCC) has high mortality. The option of systemic therapy has increased significantly over the past five years. Sorafenib was the first multikinase inhibitor, introduced in 2007, as a treatment option for HCC, and it was the only effective systemic treatment for [...] Read more.
Hepatocellular carcinoma (HCC) has high mortality. The option of systemic therapy has increased significantly over the past five years. Sorafenib was the first multikinase inhibitor, introduced in 2007, as a treatment option for HCC, and it was the only effective systemic treatment for more than ten years. It was not until 2017 that several breakthroughs were made in the development of systemic strategies. Lenvatinib, another multikinase inhibitor, stood out successfully after sorafenib, and has been applied to clinical use in the first-line setting. Other multikinase inhibitors such as regorafenib, ramucirumab and cabozantinib, were approved in quick succession as second-line therapies. Concurrently, immune checkpoint inhibitors (ICIs) have readily become established treatments for many solid tumors, including HCC. The most studied ICIs to date, target programmed cell death-1 (PD-1), its ligand PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). These ICIs have demonstrated efficacy in treating advanced HCC. More recently, combination of bevacizumab and atezolizumab (ICI targeting PD-L1) was approved as the gold-standard first-line therapy. Combination of ICIs with nivolumab and ipilimumab was also approved in the second-line setting for those who failed sorafenib. At the moment, numerous clinical trials in advanced HCC are underway, which will bring continuous change to the management, and increase the survival, for patients with advanced HCC. Our review article: (1) summarizes United States Food and Drug Administration (US FDA) approved systemic therapies in advanced HCC, (2) reports the evidence of currently approved treatments, (3) discusses potential drugs/drug combinations being currently tested in phase III clinical trials, and (4) proposes possible future directions in drug development for advanced HCC. Full article
(This article belongs to the Special Issue New Insights of Liver Cancer and Its Treatment)
Show Figures

Figure 1

Back to TopTop